OncoMatch/Clinical Trials/NCT05043571
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
Is NCT05043571 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR T-cell therapy for lymphoblastic leukemia, acute, childhood.
Treatment: CAR T-cell therapy — The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Biomarker criteria
Required: CD7 expression >99% (>99% on blast cells)
Patients with > 99% CD7 expression on blast cells will be eligible for anti-CD7 PEBL-CAR-T cell infusion.
Lab requirements
Kidney function
Normal Age-adjusted eGFR Creatinine Clearance within 3 months of screening
Liver function
Alanine aminotransferase ≤ 5 times the upper limit of normal for age
Cardiac function
Left ventricular systolic function (LVSF) ≥ 28% confirmed by echocardiogram, or left ventricular ejection fraction (LVEF) ≥ 45% confirmed by echocardiogram within 3 months of screening
Minimum level of pulmonary reserve defined as Grade ≤ 1 dyspnoea and oxygen saturation (SpO2) of > 95% on room air; Left ventricular systolic function (LVSF) ≥ 28% confirmed by echocardiogram, or left ventricular ejection fraction (LVEF) ≥ 45% confirmed by echocardiogram within 3 months of screening; Normal Age-adjusted eGFR Creatinine Clearance within 3 months of screening; Alanine aminotransferase ≤ 5 times the upper limit of normal for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify